RxDoctor Payments DataLook up a doctor →

David Oubre, MD

Hematology & Oncology · Hammond, LANPI 1104883305

Payments from drug & device makers

$1,365,576in general payments, 2019–2025

Across 1,412 payments — averaging $967.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Helsinn Healthcare SA$386K
  • AstraZeneca$154K
  • Beigene USA, Inc.$88K
  • Eli Lilly$76K
  • Genentech, Inc.$72K
  • Mirati Therapeutics, Inc.$71K
  • plus $518K from 54 others
$85,509in research payments, 2019–2025

Across 12 payments — averaging $7125.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Celltrion, Inc.$61K
  • Bristol Myers Squibb$14K
  • Pfizer$6K
  • Eli Lilly$4K
  • E.r. Squibb & Sons, L.L.C.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Helsinn Healthcare SA13$385,575
AstraZeneca(2 entities)93$154,064
Beigene USA, Inc.21$87,527
Eli Lilly3$76,138
Genentech, Inc.13$71,569
Mirati Therapeutics, Inc.22$71,005
Morphosys AG17$69,481
AbbVie39$51,922
Incyte Corporation82$42,796
Beone Medicines USA, Inc.11$38,583
Janssen Research & Development, LLC21$38,399
Astrazeneca UK Limited5$36,618
Macrogenics, Inc.29$35,419
G1 Therapeutics, Inc.19$34,765
Sanofi25$32,303
Bristol Myers Squibb51$30,531
Pfizer53$24,174
Bayer42$17,919
Daiichi Sankyo Inc.27$12,980
E.r. Squibb & Sons, L.L.C.54$8,738
Pharmacyclics LLC, An Abbvie Company50$7,548
Sobi, Inc16$6,917
Gilead(2 entities)31$4,760
Rigel Pharmaceuticals, Inc.26$4,678
TG Therapeutics, Inc.3$2,566
GSK26$2,346
Takeda Pharmaceuticals U.S.A., Inc.33$2,053
Seagen Inc.30$1,807
Novartis84$1,570
Merck50$1,110
Johnson & Johnson(2 entities)45$823
Eisai Inc.39$708
Astellas Pharma US Inc23$607
Amgen29$527
ASD Specialty Healthcare, LLC3$459
Puma Biotechnology, Inc.20$429
Genentech USA, Inc.22$415
Regeneron Healthcare Solutions, Inc.10$356
Pharmaessentia USA Corporation10$328
Spectrum Pharmaceuticals Inc.3$283
Tesaro, Inc.6$274
Morphosys, US Inc.9$268
EMD Serono, Inc.14$253
AVEO Pharmaceuticals, Inc.11$242
Karyopharm Therapeutics Inc.13$231
Dova Pharmaceuticals9$229
Blueprint Medicines Corporation12$202
Intrinsiq Specialty Solutions, Inc.1$165
Teva Pharmaceuticals USA, Inc.10$164
Ipsen Biopharmaceuticals, Inc7$155
Servier Pharmaceuticals LLC3$142
Tempus AI, Inc3$135
Array Biopharma Inc6$127
Taiho Oncology, Inc.6$123
Stemline Therapeutics Inc.6$122
Exelixis Inc.5$117
Adaptive Biotechnologies Corporation5$107
Boehringer Ingelheim5$100
Tersera Therapeutics LLC4$99
Kyowa Kirin, Inc.5$98

How this compares

$1,365,576 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.

See all hematology & oncology providers in Louisiana →

Medicare billing

Part B allowed, 2024
$2,716,029
Medicare patients
481
Services billed
201,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hammond

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →